Overview: Hepatitis A IgM TestIntroduction: The Hepatitis A IgM Test detects IgM antibodies to hepatitis A to diagnose acute infection, causing jaundice or fatigue. Following 2023 AASLD guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in serology for patients with suspected acute hepatitis A.
Other Names: Anti-HAV IgM Assay, Acute Hepatitis A Test.
FDA Status: FDA-cleared diagnostic test, meeting serology standards for diagnostic accuracy.
Historical Milestone: Hepatitis A IgM testing began in the 1970s with viral hepatitis research. Immunoassays improved in the 1980s, enhancing acute infection detection.
Purpose: Diagnoses acute hepatitis A, guides supportive care, and monitors anti-HAV IgM in patients with jaundice or fatigue.
Test Parameters: 1. Hepatitis A IgM
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like jaundice, fatigue, or nausea, and list medications.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, fatigue, nausea, or recent travel to endemic areas. Include current medications and history of hepatitis exposure.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for supportive care.
Procedural Considerations: Uses an immunoassay to detect anti-HAV IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Improper sample handling or early infection can affect results. Cross-reactivity with other infections may occur.
Clinical Significance: Positive anti-HAV IgM indicates acute hepatitis A, prompting supportive care and monitoring. Negative results may require repeat testing in early infection.
Specialist Consultation: Consult a hepatologist or infectious disease specialist for result interpretation and management planning.
Additional Supporting Tests: Anti-HAV IgG, liver function tests, or HAV PCR to confirm acute hepatitis A.
Test Limitations: False negatives may occur in very early infection. Clinical correlation is needed.
References: AASLD Hepatitis A Guidelines, 2023; Hepatology, Nelson NP, 2022.
